Meeting Banner
Abstract #5277

Comparison of Methods for Whole-Brain and Grey Matter Atrophy Assessment in Multiple Sclerosis

Loredana Storelli1, Maria A. Rocca1,2, Elisabetta Pagani1, Wim Van Hecke3, Mark A. Horsfield4, Nicola De Stefano5, Alex Rovira6, Jaume Sastre-Garriga7, Jacqueline Palace8, Diana Sima3, Dirk Smeets3, and Massimo Filippi1,2

1Neuroimaging Research Unit, INSPE, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, 2Department of Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, 3Research and Development for Icometrix, KU Leuven, Leuven, Belgium, 4Xinapse Systems, Colchester, United Kingdom, 5Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy, 6Section of Neuroradiology, Department of Radiology, Hospital Universitari Vall d’Hebron, Barcelona, Barcelona, Spain, 7Unitat de Neuroimmunologia Clinica, CEM-Cat, Hospital Universitari Vall d’Hebron, Barcelona, Spain, 8Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom

We compared different methods for whole-brain and grey matter (GM) atrophy estimation (ANTs v1.9, CIVET v2.1, FSL-SIENA(X) v5.0.1, Icometrix-MSmetrix v1.7, and SPM v12) in multiple sclerosis (MS). The accuracy and precision were evaluated for cross-sectional and longitudinal whole-brain and GM atrophy measures. All software showed high accuracy and comparable repeatability for cross-sectional measures. However, since there was poor reproducibility and high variability in cross-sectional and longitudinal atrophy measures, changes of MR scanner should be avoided. This study may help in the selection of a suitable pipeline, depending on the requirements of the application (research center, clinical setting or clinical trial).

This abstract and the presentation materials are available to members only; a login is required.

Join Here

Abstract